Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on United Therapeutics (UTHR – Research Report), retaining the price target of $354.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Terence Flynn’s rating is based on the recent FDA clearance for United Therapeutics’ innovative UKidney xenotransplantation clinical trial, aimed at addressing end-stage renal disease. The trial is notable for its utilization of gene-edited pig kidneys, which could potentially transform treatment options for patients ineligible for conventional transplants. While this development is promising, it introduces inherent uncertainties typical of early-stage clinical trials, especially in the area of xenotransplantation, which remains largely unproven.
Furthermore, Flynn’s Hold rating reflects caution due to the anticipated timeline, with the first transplants scheduled for mid-2025 and subsequent patient follow-ups extending over a lifetime. The trial’s complexity, involving multiple safety and efficacy evaluations, adds another layer of risk. Additionally, the success of such experimental therapies is not yet factored into United Therapeutics’ financial projections, prompting a more conservative investment stance at this juncture.
Based on the recent corporate insider activity of 267 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UTHR in relation to earlier this year.